Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: Oral Taxane

Study type: Interventional

Funder types: Industry

Identifiers

NCT00103831

CA165-021

Details and patient eligibility

About

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced or metastatic pretreated NSCLC
• Measurable disease
• Adequate hematologic, hepatic and renal functions.
• ECOG Performance Status 0-2

Exclusion criteria

• Inability to swallow capsules
• Recent significant cardiovascular disease
• Women who are pregnant or breastfeeding